0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Preparation of environmentally responsive PDA&DOX@LAC live drug carrier for synergistic tumor therapy

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The development of intelligent, environmentally responsive and biocompatible photothermal system holds significant importance for the photothermal combined therapy of tumors. In this study, inspired by Lactobacillus (LAC), we prepared a biomimetic nanoplatform PDA&DOX@LAC for tumor photothermal-chemotherapy by integrating the chemotherapeutic drug doxorubicin (DOX) with dopamine through oxidative polymerization to form polydopamine (PDA) on the surface of LAC. The PDA&DOX@LAC nanoplatform not only achieves precise and controlled release of DOX based on the slightly acidic microenvironment of tumor tissues, but also exhibits enzyme-like properties to alleviate tumor hypoxia. Under near-infrared light irradiation, it effectively induces photothermal ablation of tumor cells, enhances cellular uptake of DOX with increasing temperature, and thus efficiently inhibits tumor cell growth. Moreover, it is further confirmed in vivo experiments that photothermal therapy combined with PDA&DOX@LAC induces tumor cells apoptosis, releases tumor-associated antigens, which is engulfed by dendritic cells to activate cytotoxic T lymphocytes, thereby effectively suppressing tumor growth and prolonging the survival period of 4T1 tumor-bearing mice. Therefore, the PDA&DOX@LAC nanoplatform holds immense potential in precise tumor targeting as well as photothermal combined therapy and provides valuable insights and theoretical foundations for the development of novel tumor treatment strategies based on endogenous substances within the body.

          Related collections

          Most cited references60

          • Record: found
          • Abstract: not found
          • Article: not found

          Polydopamine and its derivative materials: synthesis and promising applications in energy, environmental, and biomedical fields.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Clinical development and potential of photothermal and photodynamic therapies for cancer

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Tumour-targeting bacteria engineered to fight cancer

              Recent advances in targeted therapy and immunotherapy have once again raised the hope that a cure might be within reach for many cancer types. Yet, the majority of cancers are either insensitive to the therapies to begin with or develop resistance later on. Therapy with live tumor-targeting bacteria provides a unique option to meet these challenges. Compared to most other therapeutics, the effectiveness of tumor-targeting bacteria is not directly affected by the genetic makeup of a tumor. Bacteria initiate their direct antitumor effects from deep within the tumor, followed by innate and adaptive antitumor immune responses. As microscopic “robotic factories”, bacterial vectors can be reprogrammed following simple genetic rules or sophisticated synthetic bioengineering principles to produce and deliver anticancer agents based on clinical needs. Therapeutic approaches using live tumor-targeting bacteria can either be applied as a monotherapy or complement other anticancer therapies to achieve better clinical outcomes. In this Review, we summarize the potential benefits and challenges of this approach. We discuss how live bacteria selectively induce tumor regression and provide examples to illustrate different ways to engineer bacteria for improved safety and efficacy. Finally, we share our experience and insights on oncology clinical trials with tumor-targeting bacteria, including a discussion on regulatory issues.
                Bookmark

                Author and article information

                Contributors
                18051061782@189.cn
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                10 July 2024
                10 July 2024
                2024
                : 14
                : 15927
                Affiliations
                [1 ]Northern Jiangsu People’s Hospital, ( https://ror.org/04gz17b59) Yangzhou, 225001 People’s Republic of China
                [2 ]The Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’an, ( https://ror.org/02sqxcg48) No. 62, Huaihai Road (S.), Huai’an, 223002 People’s Republic of China
                Article
                66966
                10.1038/s41598-024-66966-2
                11236969
                38987493
                b3610c97-f4a1-4143-a189-c62d301d9e4c
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 11 April 2024
                : 5 July 2024
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100004608, Natural Science Foundation of Jiangsu Province;
                Award ID: SBK2020022937
                Award Recipient :
                Categories
                Article
                Custom metadata
                © Springer Nature Limited 2024

                Uncategorized
                polydopamine,combination therapy,environmental response,precise release,cancer,drug discovery,immunology,materials science

                Comments

                Comment on this article